Tag Archive for: TAVO-EP (tavokinogene telseplasmid)

Cancer immunotherapy biotech OncoSec Medical Inc. will lay off around 45% of its workforce to focus its resources on the development of its lead asset, TAVO-EP (tavokinogene telseplasmid), the company announced Tuesday.